在早期乳腺癌中使用多模式降级策略
Icro Meattini1,2, Ana Tecic Vuger3, Carlotta Becherini2
1Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Florence, Italy.
概括
早期乳腺癌 (EBC) 的治疗降级旨在降低治疗负担,同时保持高治愈率. 关键策略包括在特定患者中省略哨兵淋巴结活检和化疗 (CTx),以生物标志物为指导.
科学领域:
- 在瘤学瘤学.
- 乳腺癌研究研究 乳腺癌研究
- 临床试验设计 临床试验设计
背景情况:
- 目前的早期乳腺癌 (EBC) 治疗实现了优异的治愈率,为缓解升级设定了高标准.
- 治疗降级必须整合到多模式治疗策略中,以避免其他模式的补偿性升级.
研究的目的:
- 审查目前的证据和策略,以缓解早期乳腺癌 (EBC) 的升级治疗.
- 突出生物标志物和多模式治疗概念在安全降级中的作用.
- 强调需要基于证据的缓和,并通过未来的试验来验证.
主要方法:
- 对临床试验数据和EBC当前治疗指南的审查.
- 分析手术,放射治疗 (RT) 和化疗 (CTx) 的降级策略.
- 评估生物标志物的实用性,包括基因表达试验和Ki67的确定.
主要成果:
- 省略哨兵淋巴结活检对于低风险的激素受体阳性/人表皮生长因子受体2-阴性 (HER2-) 疾病是安全的.
- 通过质量保证,将手术和RT调整为全身治疗反应是可行的.
- 基因表达试验和Ki67评估对特定EBC患者群体的化学疗法 (CTx) 省略有助.
结论:
- 在EBC中治疗降级可以减少治疗负担而不会影响结果.
- 生物标志物驱动的降级,例如省略哨兵淋巴结活检和化疗 (CTx),得到证据的支持.
- 通过前性临床试验进行持续验证对于降级概念和生物标志物至关重要.
更多相关视频
相关概念视频
02:49Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K